PRELIMINARY INVESTIGATION ON THE PHYSICAL PROPERTIES AND MORPHOLOGICAL OF SINTERED COCKLE SHELL/RECYCLED SODA LIME SILICATE COMPOSITE

The effect of treatment condition cockle shell (CS) on physical properties, phases and morphology behaviour of CS filler/recycled soda lime silicate glass (rSLSG) composite were investigated. The CS filler was prepared at drying condition and calcined at temperature of 800 °C and 1000 °C before subjected to the direct sintering process. The crystalline phases present in the treated samples of CS fller and composite were identified by X-ray diffraction (RIGAKU MINIFLEX II) and was observed that CaO fully precipitated when the calcination temperature was increased to 1000 °C and quartz phases predominate at high volume glass content. The tested samples were characterized using Fourier transform infrared spectroscopy (FTIR) and confirmed hydrogen bond affected densification of CS/rSLSG composite. This composite was tested using physical testing and results revealed that the average of porosity, water absorption, and bulk density was a function of calcination temperatures. Scanning electron microscope shows observation on CS filler revealed that the treatment condition led the phase separation of the cluster interconnected before the skeleton crystals shape formed at 1000 °C. The findings concluded that the suitable composition for CS filler loading was 30 wt.% and can be controlled for building material applications

Structural behavior of mortarless interlocking load bearing hollow block wall panel under out-of-plane loading.

Experimental and numerical investigation of interlocking mortarless wall panels with 1.0 m height, 1.2 m width and 150 mm thickness are conducted. Behaviour of both hollow and partially grouted masonry wall panels is studied. The panels were tested under constant pre-compressive vertical load and out-of-plane lateral load. Lateral load carrying capacity, deflection at mid height, dry joint opening between block layers and mode of failure are investigated. Strain characteristics throughout the loading process are also monitored. A finite element analysis is presented for the system and a good agreement between the experimental and modelling results is achieved. Parametric study using the finite element model is also presented and the effect of different parameters; amount of pre-compressive load and slenderness ratio is studied. The study reveals that pre-compressive vertical load and reinforcement significantly affect the structural behaviour of mortarless walls under out-of-plane loading. Useful expressions for the capacity are obtained from the analysis

Elucidation of interactive effects of synthesis conditions on the characteristics of mesoporous silicas templated using polyoxide surfactant

A series of mesoporous silicas (MS-1–MS-9) were synthesized at different gel compositions using a triblock copolymer (TCP), poly(ethylene oxide)–poly(propylene oxide)–poly(ethylene oxide), as the surfactant. The interactive effects of acidity, the contents of tetraethyl orthosilicate (TEOS) and the surfactant, and the gelling temperature on the characteristics of the final material were simultaneously characterized. Increasing acidity favored mesopore formation. A material with a surface area of 760 m2/g, mostly in the mesoporous range, was obtained at 1.0(TEOS):0.017(TCP):7.3HCl:115.7H2O. Mesopore formation was predominantly determined by the TEOS:TCP ratio and was promoted with its increase from 1.56:1 to 2.09:1. A further increase to 2.61:1 was detrimental. Whereas increasing the TCP content to 3.5% w/w improved micellization, a further increase to 4.6% should be avoided. Mesoporous silicas showed low crystallinity but a high degree of hexagonal mesoscopic organization. The weak surface acidity was attributed to surface silanols, the number of which was proportional to mesoporosity

Kaposi sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from sub-Saharan Africa, Europe, and Asia

BACKGROUND  The burden of Kaposi sarcoma (KS) in human immunodeficiency virus (HIV)-infected children and adolescents on combination antiretroviral therapy (cART) has not been compared globally. METHODS  We analyzed cohort data from the International Epidemiologic Databases to Evaluate AIDS and the Collaboration of Observational HIV Epidemiological Research in Europe. We included HIV-infected children aged <16 years at cART initiation from 1996 onward. We used Cox models to calculate hazard ratios (HRs), adjusted for region and origin, sex, cART start year, age, and HIV/AIDS stage at cART initiation. RESULTS  We included 24 991 children from eastern Africa, southern Africa, Europe and Asia; 26 developed KS after starting cART. Incidence rates per 100 000 person-years (PYs) were 86 in eastern Africa (95% confidence interval [CI], 55-133), 11 in southern Africa (95% CI, 4-35), and 81 (95% CI, 26-252) in children of sub-Saharan African (SSA) origin in Europe. The KS incidence rates were 0/100 000 PYs in children of non-SSA origin in Europe (95% CI, 0-50) and in Asia (95% CI, 0-27). KS risk was lower in girls than in boys (adjusted HR [aHR], 0.3; 95% CI, .1-.9) and increased with age (10-15 vs 0-4 years; aHR, 3.4; 95% CI, 1.2-10.1) and advanced HIV/AIDS stage (CDC stage C vs A/B; aHR, 2.4; 95% CI, .8-7.3) at cART initiation. CONCLUSIONS  HIV-infected children from SSA but not those from other regions, have a high risk of developing KS after cART initiation. Early cART initiation in these children might reduce KS risk

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Data were assessed overall and by WHO regions, sex, and index versus non-index cases. Findings Of the 61 612 individuals in the registry, 42 167 adults (21 999 [53·6%] women) from 56 countries were included in the study. Of these, 31 798 (75·4%) were diagnosed with the Dutch Lipid Clinic Network criteria, and 35 490 (84·2%) were from the WHO region of Europe. Median age of participants at entry in the registry was 46·2 years (IQR 34·3–58·0); median age at diagnosis of familial hypercholesterolaemia was 44·4 years (32·5–56·5), with 40·2% of participants younger than 40 years when diagnosed. Prevalence of cardiovascular risk factors increased progressively with age and varied by WHO region. Prevalence of coronary disease was 17·4% (2·1% for stroke and 5·2% for peripheral artery disease), increasing with concentrations of untreated LDL cholesterol, and was about two times lower in women than in men. Among patients receiving lipid-lowering medications, 16 803 (81·1%) were receiving statins and 3691 (21·2%) were on combination therapy, with greater use of more potent lipid-lowering medication in men than in women. Median LDL cholesterol was 5·43 mmol/L (IQR 4·32–6·72) among patients not taking lipid-lowering medications and 4·23 mmol/L (3·20–5·66) among those taking them. Among patients taking lipid-lowering medications, 2·7% had LDL cholesterol lower than 1·8 mmol/L; the use of combination therapy, particularly with three drugs and with proprotein convertase subtilisin–kexin type 9 inhibitors, was associated with a higher proportion and greater odds of having LDL cholesterol lower than 1·8 mmol/L. Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular risk factors and cardiovascular diseases (all p<0·001). Interpretation Familial hypercholesterolaemia is diagnosed late. Guideline-recommended LDL cholesterol concentrations are infrequently achieved with single-drug therapy. Cardiovascular risk factors and presence of coronary disease were lower among non-index cases, who were diagnosed earlier. Earlier detection and greater use of combination therapies are required to reduce the global burden of familial hypercholesterolaemia. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron